Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer

Front Oncol. 2021 Mar 17;11:632657. doi: 10.3389/fonc.2021.632657. eCollection 2021.

NO ABSTRACT

PMID:33816271 | PMC:PMC8018233 | DOI:10.3389/fonc.2021.632657